PERSPECTIVE article
Front. Oncol.
Sec. Cancer Genetics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1599753
Personalized Preventive Medicine Using Genomic Information: Future Perspective and Corresponding Research Plan
Provisionally accepted
- 1Kanagawa Cancer Center, Yokohama, Japan
- 2Kanagawa University of Human Services, Yokosuka, Kanagawa, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Personalized cancer screening guided by genomic information holds the potential for effective cancer prevention. However, current approaches face challenges, including the low risk associated with most genetic variants and limited experience in genetic counseling for healthy individuals. We are initiating a feasibility study that employs a germline cancer genomic panel of 30-80 high-risk cancer genes, such as BRCA1 and BRCA2, to identify individuals with pathogenic variants. Genetic counseling will be conducted by certified medical doctors and genetic counselors utilizing the Kanagawa Prospective "ME-BYO" Cohort Study. This initiative seeks to adapt hereditary cancer counseling practices to preventive medicine, addressing the differences in counseling between clinical and preventive settings. It aims to establish a framework for personalized cancer screening, contributing to future guidelines for identifying individuals at high risk of hereditary cancers. This research will help bridge the gap between genomic research and practical preventive medicine, paving the way for personalized cancer screening strategies based on genetic information.
Keywords: Hereditary tumor, artificial intelligence, breast cancer, Germ-line cells, cancer screening
Received: 26 Mar 2025; Accepted: 12 May 2025.
Copyright: © 2025 Narimatsu, Watanabe, Sato, Haneda, Okamoto, Nakada and Nakamura. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hiroto Narimatsu, Kanagawa Cancer Center, Yokohama, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.